Jazz Pharmaceuticals (JAZZ) Other Operating Expenses (2010 - 2026)

Jazz Pharmaceuticals' Other Operating Expenses history runs 17 years deep, the most recent figure standing at $122.8 million for Q1 2026.

• In Q1 2026, Other Operating Expenses changed N/A year-over-year to $122.8 million; the TTM figure through Mar 2026 stood at $2.0 billion (up 139.66% YoY), while the FY2025 annual figure was $2.1 billion, up 94.44% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $122.8 million, down from $323.3 million in the prior quarter.
• The five-year high for Other Operating Expenses was $1.2 billion in Q2 2025, with the low at $122.8 million in Q1 2026.
• The 5-year median for Other Operating Expenses is $283.4 million (2022), against an average of $364.6 million.
• The sharpest annual moves came in 2023 and 2025: Other Operating Expenses plunged 59.28% in 2023, then surged 346.48% in 2025.
• Jazz Pharmaceuticals' Other Operating Expenses stood at $679.8 million in 2022, then slumped by 59.28% to $276.8 million in 2023, then increased by 3.91% to $287.6 million in 2024, then rose by 12.4% to $323.3 million in 2025, then tumbled by 62.01% to $122.8 million in 2026.
• Business Quant data shows JAZZ's Other Operating Expenses at $122.8 million in Q1 2026, $323.3 million in Q4 2025, and $339.7 million in Q3 2025.